Skip to main content
      A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-in-class peptide that binds and blocks the interleukin-23 receptor (IL-23R), is showing encouraging efficacy and safety across a range of psoriasis (PSO) and psoriatic disease (PsD) studies.
      After several failures of therapies in Phase 3 trials of Sjogren’s disease (SjD) over many years, all hope is not lost! At this year’s ACR25 Convergence Conference in Chicago, not one but two drugs presented their efficacy and safety data in patients with moderate to severe disease activity as defined by ESSDAI score ≥ 5 points.
      At ACR Convergence 2025, abstract 1039 entitled, “Global Cost-Effectiveness and Equity in CAR-T Cell Therapy for Rheumatoid Arthritis” adds a critical dimension to the growing enthusiasm around cellular therapies in autoimmune disease.
      RheumNow’s expanded coverage of the #ACR25 meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All covera

      Dr. John Cush RheumNow

      6 days 1 hour ago
      RheumNow’s expanded coverage of the #ACR25 meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is selected by RheumNow and its faculty.
      CAR-T Cell Therapies Show Promise for Autoimmune Disease

      Two pioneering studies presented at #ACR25 spotlight the poten

      Dr. John Cush RheumNow

      6 days 1 hour ago
      CAR-T Cell Therapies Show Promise for Autoimmune Disease Two pioneering studies presented at #ACR25 spotlight the potential of CAR-T cell therapies to transform treatment for SLE and other autoimmune diseases. These early findings suggest a new frontier in immune modulation and https://t.co/KdNWmVc4Qc
      ACR2025 Day 4 Recap https://t.co/YaWB9iVMsy

      Dr. John Cush RheumNow

      6 days 2 hours ago
      ACR2025 Day 4 Recap https://t.co/YaWB9iVMsy
      Meta analysis evaluating age specific incidence across multiple registries (n=882)

      Incidence 9.3 for women & 1.4 fo

      Mike Putman EBRheum

      6 days 3 hours ago
      Meta analysis evaluating age specific incidence across multiple registries (n=882) Incidence 9.3 for women & 1.4 for men per 100k person-years 1. Wider distribution than I would have guessed 2. Much less age-dependency for men @RheumNow #ACR25 Abstr#29W06 https://t.co/46dNGBZ45V
      Phase 1 study of CAR-Treg in difficult to treat RA

      4/6 pts had 50% reduction in TJC/SJC, no CYC/fludrabine required &am

      Mike Putman EBRheum

      6 days 3 hours ago
      Phase 1 study of CAR-Treg in difficult to treat RA 4/6 pts had 50% reduction in TJC/SJC, no CYC/fludrabine required & good prelim safety data CAR-T remains exciting, but less of the "totally magical everyone cured" stuff we saw w/initial CAR-T reports @RheumNow #ACR25 https://t.co/kjBIkLCYpF
      "Achieving good control of joint disease activity is probably the key objective of treatment of patients with RA-ILD"
      -

      Mike Putman EBRheum

      6 days 3 hours ago
      "Achieving good control of joint disease activity is probably the key objective of treatment of patients with RA-ILD" - Gregory McDermott (Epi Abstracts, #2662) Totally agree with this! SARD guidelines recommendingn drugs with mediocre activity in RA was surprising @RheumNow
      Excited about this target trial emulation in RA-ILD

      Compared to RTX, NO significant difference in hospitalization/trans

      Mike Putman EBRheum

      6 days 3 hours ago
      Excited about this target trial emulation in RA-ILD Compared to RTX, NO significant difference in hospitalization/transplant/death for JAK, ABA, IL6 or TNF Trends toward ABA and JAK looking better than RTX Need trials for sure, but I like this project a lot @RheumNow #ACR25 https://t.co/FQcphRvyHK
      Coping Strategies in axSpA
      ×